Amedisys, Inc. (NASDAQ:AMED) Q1 2022 Earnings Conference Call April 28, 2022 11:00 AM ET
Company Participants
Nick Muscato - Chief Strategy Officer
Christopher Gerard - CEO, President & Director
Scott Ginn - EVP & CFO
David Kemmerly - Chief Legal & Government Affairs Officer
Conference Call Participants
Brian Tanquilut - Jefferies
Matthew Larew - William Blair & Company
Justin Bowers - Deutsche Bank
John Ransom - Raymond James & Associates
Matthew Borsch - BMO Capital Markets
Andrew Mok - UBS
Benjamin Mayo - SVB Leerink
Sarah James - Barclays Bank
Joanna Gajuk - Bank of America Merrill Lynch
Albert Rice - Crédit Suisse
Operator
Greetings, and welcome to Amedisys' Q1 '22 Earnings Conference Call. [Operator Instructions].
I would now like to turn the conference over to your host, Nick Muscato, Chief Strategy Officer. Please go ahead, sir.
Nick Muscato
Thank you, operator, and welcome to the Amedisys investor conference call to discuss the results of the first quarter ended March 31, 2022. A copy of our press release, supplemental slides and related Form 8-K filing with the SEC are available on the Investor Relations page of our website. Speaking on today's call from Amedisys will be President and Chief Executive Officer, Chris Gerard; [indiscernible] also joining us is Dave Kemmerly, Chief Legal and Government Affairs Officer. .
Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Amedisys today.
The company assumes no obligation to update information provided on this call to reflect subsequent events other than as required under applicable securities laws. These forward-looking statements may involve a number of risks and uncertainties, which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our Forms 10-K, 10-Q and 8-K.
In addition, as required by SEC Regulation G, a reconciliation of any non-GAAP measure mentioned during our call today to the most comparable GAAP measure will be available in our Forms 10-K, 10-Q and 8-K.
Thank you. And now I'll turn the call over to President and CEO, Chris Gerard.
Christopher Gerard
Thanks, Nick, and thanks to everyone for joining us. Today, Amedisys announced our first quarter 2022 results, which reflect the resilience of our core business driven by our strategy that continues to differentiate us in our markets.